Autopsy report · NCT05366855

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

“AnaptysBio has concluded the GEMINI-2 trial, with all trial participants having been treated with imsidolimab for approximately six months and the furthest subject having been treated through 104 weeks.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 3 months before it stopped.
• 42 participants enrolled.
• Results were posted on the registry 1 year 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Vanda Pharmaceuticals

Sponsor type

Industry

Conditions

Generalized Pustular Psoriasis

Interventions

Double-blind 200 mg imsidolimab; Placebo; Open-label 200 mg imsidolimab; Standard of Care (SOC); Imsidolimab 750 mg IV/200 mg SC

Participants

42

Sites

65

Countries

Australia, France, Georgia, Germany, Malaysia, Morocco, Poland, Romania, South Korea, Spain, Taiwan, Thailand and more

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.